JP2007055992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007055992A5 JP2007055992A5 JP2005319615A JP2005319615A JP2007055992A5 JP 2007055992 A5 JP2007055992 A5 JP 2007055992A5 JP 2005319615 A JP2005319615 A JP 2005319615A JP 2005319615 A JP2005319615 A JP 2005319615A JP 2007055992 A5 JP2007055992 A5 JP 2007055992A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- isoleucine
- leucine
- glutamine
- perioperative patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 22
- 229960000310 ISOLEUCINE Drugs 0.000 claims description 19
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 19
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 239000000863 peptide conjugate Substances 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 17
- 229940079593 drugs Drugs 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 230000036760 body temperature Effects 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 229960001230 Asparagine Drugs 0.000 claims description 11
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 11
- 229960002989 Glutamic Acid Drugs 0.000 claims description 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 11
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 11
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 11
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 11
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 11
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 11
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 11
- 229960003104 Ornithine Drugs 0.000 claims description 11
- 229960005190 Phenylalanine Drugs 0.000 claims description 11
- 229960003080 Taurine Drugs 0.000 claims description 11
- 239000004473 Threonine Substances 0.000 claims description 11
- 235000004279 alanine Nutrition 0.000 claims description 11
- 235000009582 asparagine Nutrition 0.000 claims description 11
- 235000013922 glutamic acid Nutrition 0.000 claims description 11
- 239000004220 glutamic acid Substances 0.000 claims description 11
- 239000004474 valine Substances 0.000 claims description 11
- 235000014393 valine Nutrition 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229960005261 Aspartic Acid Drugs 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical group C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 4
- 229960002648 alanylglutamine Drugs 0.000 claims description 4
- 108010044940 alanylglutamine Proteins 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 4
- 206010062519 Poor quality sleep Diseases 0.000 claims description 3
- 230000037007 arousal Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
Description
表７
次に、本発明の好ましい態様を示す。
1. バリン、アスパラギン酸、システイン、グリシン、アラニン、プロリン、セリン、ロイシン、フェニルアラニン、イソロイシン、スレオニン、ヒスチジン、チロシン、グルタミン酸、グルタミン、オルニチン、アスパラギン、タウリン及びこれらのペプチド結合体からなる群から選択される少なくとも１種を有効成分として含有することを特徴とする周術期患者用薬剤。
2. バリン、アスパラギン酸、システイン、グリシン、アラニン、プロリン、セリン、ロイシン、フェニルアラニン、イソロイシン、スレオニン、ヒスチジン、チロシン、グルタミン酸、グルタミン、オルニチン、アスパラギン及びタウリンからなる群から選択される少なくとも２種を有効成分として含有することを特徴とする周術期患者用薬剤。
3. 少なくともイソロイシンおよびロイシンの何れか１つを有効成分として含有することを特徴とする周術期患者用薬剤。
4. イソロイシン、ロイシン及びバリンを有効成分として含有することを特徴とする周術期患者用薬剤。
5. ペプチド結合体が、請求項１記載の２つの化合物のペプチド結合体である請求項１記載の周術期患者用薬剤。
6. ペプチド結合体が、アラニル−グルタミンである請求項５記載の周術期患者用薬剤。
7. 輸液製剤の形態である請求項１〜６のいずれか１項記載の周術期患者用薬剤。
8. 更に電解質を含有する請求項７記載の周術期患者用薬剤。
9. 飲食品の形態である請求項１〜６のいずれか１項記載の周術期患者用薬剤。
10. アラニン、プロリン、セリン、ロイシン、フェニルアラニン、イソロイシン、スレオニン、ヒスチジン、チロシン、グルタミン酸、グルタミン、オルニチン、アスパラギン、タウリン及びこれらのペプチド結合体からなる群から選択される少なくとも１種を有効成分として含有することを特徴とする体温低下抑制剤。
11. アラニン、プロリン、セリン、ロイシン、フェニルアラニン、イソロイシン、スレオニン、ヒスチジン、チロシン、グルタミン酸、グルタミン、オルニチン、アスパラギン及びタウリンからなる群から選択される少なくとも２種を有効成分として含有することを特徴とする体温低下抑制剤。
12. 少なくともイソロイシンおよびロイシンの何れか１つを有効成分として含有することを特徴とする体温低下抑制剤。
13. イソロイシン、ロイシン及びバリンを有効成分として含有することを特徴とする体温低下抑制剤。
14. ペプチド結合体が、請求項１０記載の２つの化合物のペプチド結合体である請求項１０記載の体温低下抑制剤。
15. ペプチド結合体が、アラニル−グルタミンである請求項１４記載の体温低下抑制剤。
16. 医薬品の形態である請求項９〜１５のいずれか１項記載の体温低下抑制剤。
17. 医薬品が輸液製剤の形態である請求項１６記載の体温低下抑制剤。
18. アラニン、プロリン、セリン、ロイシン、フェニルアラニン、イソロイシン、スレオニン、ヒスチジン、チロシン、グルタミン酸、グルタミン、オルニチン、アスパラギン及びタウリンのいずれかの濃度が０．０１〜１０Ｗ／Ｖ％である請求項１０又は１１記載の体温低下抑制剤。
19. 更に電解質を含有することを特徴とする請求項１０〜１８のいずれか１項記載の体温低下抑制剤。
20. 使用時に輸液製剤に配合することを特徴とする請求項１６〜１９のいずれか１項記載の体温低下抑制剤。
21. 飲食品の形態である請求項１０〜１５のいずれか記載の体温低下抑制剤。
22. 周術期合併症を予防および／あるいは改善する請求項１０〜２１のいずれか１項記載の体温低下抑制剤。
23. バリン、アスパラギン酸、システイン、グリシン、アラニン、プロリン、セリン、ロイシン、フェニルアラニン、イソロイシン、スレオニン、ヒスチジン、チロシン、グルタミン酸、グルタミン、オルニチン、アスパラギン、タウリン及びこれらのペプチド結合体からなる群から選択される少なくとも１種を有効成分として含有することを特徴とする覚醒遅延防止剤。
24. バリン、アスパラギン酸、システイン、グリシン、アラニン、プロリン、セリン、ロイシン、フェニルアラニン、イソロイシン、スレオニン、ヒスチジン、チロシン、グルタミン酸、グルタミン、オルニチン、アスパラギン及びタウリンからなる群から選択される少なくとも２種を有効成分として含有することを特徴とする覚醒遅延防止剤。
25. 少なくともイソロイシンおよびロイシンの何れか１つを有効成分として含有することを特徴とする覚醒遅延防止剤。
26. イソロイシン、ロイシン及びバリンを有効成分として含有することを特徴とする覚醒遅延防止剤。
27. ペプチド結合体が、請求項２３記載の２つの化合物のペプチド結合体である請求項２３記載の覚醒遅延防止剤。
28. ペプチド結合体が、アラニル−グルタミンである請求項２７記載の覚醒遅延防止剤。
29. 医薬品の形態である請求項２３〜２８のいずれか１項記載の覚醒遅延防止剤。
30. 医薬品が輸液製剤の形態である請求項２９記載の覚醒遅延防止剤。
31. 更に電解質を含有する請求項３０記載の覚醒遅延防止剤。
32. 飲食品の形態である請求項２３〜２８のいずれか１項記載の覚醒遅延防止剤。
Table 7
Next, a preferred embodiment of the present invention will be shown.
1. selected from the group consisting of valine, aspartic acid, cysteine, glycine, alanine, proline, serine, leucine, phenylalanine, isoleucine, threonine, histidine, tyrosine, glutamic acid, glutamine, ornithine, asparagine, taurine and their peptide conjugates A drug for perioperative patients, comprising at least one of these as an active ingredient.
2. Effective at least two selected from the group consisting of valine, aspartic acid, cysteine, glycine, alanine, proline, serine, leucine, phenylalanine, isoleucine, threonine, histidine, tyrosine, glutamic acid, glutamine, ornithine, asparagine and taurine A drug for perioperative patients characterized by containing as a component.
3. A drug for perioperative patients, comprising at least one of isoleucine and leucine as an active ingredient.
4. A drug for perioperative patients comprising isoleucine, leucine and valine as active ingredients.
5. The drug for perioperative patients according to claim 1, wherein the peptide conjugate is a peptide conjugate of the two compounds according to claim 1.
6. The drug for perioperative patients according to claim 5, wherein the peptide conjugate is alanyl-glutamine.
7. The drug for perioperative patients according to any one of claims 1 to 6, which is in the form of an infusion preparation.
8. The drug for perioperative patients according to claim 7, further comprising an electrolyte.
9. The drug for perioperative patients according to any one of claims 1 to 6, which is in the form of a food or drink.
10. Contains at least one selected from the group consisting of alanine, proline, serine, leucine, phenylalanine, isoleucine, threonine, histidine, tyrosine, glutamic acid, glutamine, ornithine, asparagine, taurine and their peptide conjugates as an active ingredient A body temperature decrease inhibitor characterized by:
11. It contains at least two kinds selected from the group consisting of alanine, proline, serine, leucine, phenylalanine, isoleucine, threonine, histidine, tyrosine, glutamic acid, glutamine, ornithine, asparagine and taurine as active ingredients. Body temperature reduction inhibitor.
12. A body temperature lowering inhibitor comprising at least one of isoleucine and leucine as an active ingredient.
13. A body temperature lowering inhibitor comprising isoleucine, leucine and valine as active ingredients.
14. The body temperature lowering inhibitor according to claim 10, wherein the peptide conjugate is a peptide conjugate of the two compounds according to claim 10.
15. The body temperature lowering inhibitor according to claim 14, wherein the peptide conjugate is alanyl-glutamine.
16. The body temperature decrease inhibitor according to any one of claims 9 to 15, which is in the form of a pharmaceutical product.
17. The body temperature decrease inhibitor according to claim 16, wherein the pharmaceutical is in the form of an infusion preparation.
18. The concentration of any one of alanine, proline, serine, leucine, phenylalanine, isoleucine, threonine, histidine, tyrosine, glutamic acid, glutamine, ornithine, asparagine and taurine is 0.01 to 10 W / V%. The body temperature reduction inhibitor as described.
19. The body temperature lowering inhibitor according to any one of claims 10 to 18, further comprising an electrolyte.
20. The body temperature decrease inhibitor according to any one of claims 16 to 19, which is formulated into an infusion preparation at the time of use.
21. The body temperature decrease inhibitor according to any one of claims 10 to 15, which is in the form of a food or drink.
22. The body temperature lowering inhibitor according to any one of claims 10 to 21, which prevents and / or improves perioperative complications.
23. selected from the group consisting of valine, aspartic acid, cysteine, glycine, alanine, proline, serine, leucine, phenylalanine, isoleucine, threonine, histidine, tyrosine, glutamic acid, glutamine, ornithine, asparagine, taurine and their peptide conjugates A wakefulness delay-preventing agent, comprising at least one active ingredient as an active ingredient.
24. Effective at least two selected from the group consisting of valine, aspartic acid, cysteine, glycine, alanine, proline, serine, leucine, phenylalanine, isoleucine, threonine, histidine, tyrosine, glutamic acid, glutamine, ornithine, asparagine and taurine A wakefulness delay inhibitor characterized by containing as a component.
25. An agent for preventing arousal delay, containing at least one of isoleucine and leucine as an active ingredient.
26. An agent for preventing arousal delay, comprising isoleucine, leucine and valine as active ingredients.
27. The agent for preventing arousal delay according to claim 23, wherein the peptide conjugate is a peptide conjugate of the two compounds according to claim 23.
28. The agent for preventing arousal delay according to claim 27, wherein the peptide conjugate is alanyl-glutamine.
29. The agent for preventing arousal delay according to any one of claims 23 to 28, which is in the form of a pharmaceutical product.
30. The agent for preventing arousal delay according to claim 29, wherein the pharmaceutical is in the form of an infusion preparation.
31. The agent for preventing awakening delay according to claim 30, further comprising an electrolyte.
32. The agent for preventing arousal delay according to any one of claims 23 to 28, which is in the form of a food or drink.
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005319615A JP5177785B2 (en) | 2004-11-02 | 2005-11-02 | Drugs for perioperative patients |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004319375 | 2004-11-02 | ||
| JP2004319375 | 2004-11-02 | ||
| JP2005219281 | 2005-07-28 | ||
| JP2005219281 | 2005-07-28 | ||
| JP2005319615A JP5177785B2 (en) | 2004-11-02 | 2005-11-02 | Drugs for perioperative patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007055992A JP2007055992A (en) | 2007-03-08 |
| JP2007055992A5 true JP2007055992A5 (en) | 2008-12-18 |
| JP5177785B2 JP5177785B2 (en) | 2013-04-10 |
Family
ID=37919777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005319615A Expired - Fee Related JP5177785B2 (en) | 2004-11-02 | 2005-11-02 | Drugs for perioperative patients |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5177785B2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI445540B (en) | 2007-04-20 | 2014-07-21 | Ajinomoto Kk | Anti-hypothermia composition |
| JP2011241149A (en) * | 2010-05-14 | 2011-12-01 | Terumo Corp | Digestible oral nutrient |
| JP5997425B2 (en) * | 2011-08-18 | 2016-09-28 | 協和発酵バイオ株式会社 | Ornithine-containing composition |
| JP2014159381A (en) * | 2013-02-19 | 2014-09-04 | Kyowa Hakko Bio Co Ltd | Ornithine-containing composition for improving body composition |
| JOP20190146A1 (en) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | Amino acid compositions and methods for the treatment of liver diseases |
| EP3668499A1 (en) | 2017-08-14 | 2020-06-24 | Axcella Health Inc. | Amino acid compositions for the treatment of liver disease |
| CN112839643A (en) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | Compositions and methods for treating fat infiltration in muscle |
| CN108721596B (en) * | 2018-06-29 | 2021-09-21 | 复旦大学附属中山医院 | Compound amino acid vitamin injection and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8704217D0 (en) * | 1987-10-29 | 1987-10-29 | Vinnars Erik Ab | AMINO ACID COMPOSITION FOR PARENTERAL NUTRITION |
| JPH02128670A (en) * | 1988-11-08 | 1990-05-17 | Ajinomoto Co Inc | Amino acid-containing food composition |
| JPH03264525A (en) * | 1990-03-14 | 1991-11-25 | Otsuka Pharmaceut Factory Inc | Amino acid infusion solution |
| JPH0710770A (en) * | 1990-03-14 | 1995-01-13 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion solution |
| JPH06227974A (en) * | 1993-01-29 | 1994-08-16 | Kyowa Hakko Kogyo Co Ltd | Nutritive composition |
| EP1591116A4 (en) * | 2003-02-06 | 2008-05-28 | Otsuka Pharma Co Ltd | Inhibitor for perioperative blood sugar elevation |
-
2005
- 2005-11-02 JP JP2005319615A patent/JP5177785B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007055992A5 (en) | ||
| JP2018012722A5 (en) | ||
| GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
| HK1096034A1 (en) | A solid dosage form comprising a fibrate | |
| DE602005021770D1 (en) | INDOLE-1-YL-ACETIC DERIVATIVES | |
| EA201201265A1 (en) | COMPOSITION (OPTIONS), METHOD FOR ITS PREPARATION, TANK CONTAINING CONTAINING THE SPECIFIED COMPOSITION, AND METHOD FOR TREATING VIRAL DISEASES WITH ITS USE | |
| MXPA06002344A (en) | Pharmaceutical compositions and method of using levodopa and carbidopa. | |
| DK1885333T3 (en) | Pharmaceutical formulation of apomorphine for buccal administration | |
| EA200701923A1 (en) | DRUG FORM FOR THE ORAL ADMINISTRATION OF VITAMIN | |
| WO2005046569A3 (en) | Pharmaceutical compositions for the treatment of sars | |
| RU2007149474A (en) | MEANS FOR PREVENTION AND TREATMENT OF LIVER DISEASES CONTAINING A PYRAZOLOPYRIMIDINONE DERIVATIVE | |
| JP6018048B2 (en) | Ibuprofen pharmaceutical composition for injection | |
| JP2011530540A5 (en) | ||
| EP1752146A4 (en) | Therapeutic agent for diabetes | |
| JPWO2002100193A1 (en) | Body temperature raising amino acid group | |
| WO2007055887A1 (en) | Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same | |
| WO2007035718A3 (en) | Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8-aminocaprylic acid | |
| JP2010059120A (en) | Oral amino-acid preparation having improved easiness to take | |
| WO2003045305A3 (en) | Acetaminophen compositions | |
| WO2010044582A2 (en) | Ｎ1-2-thiophene-2-ylethyl-ｎ2-substituted biguanide derivate, preparation method thereof, and pharmaceutical composition containing the same as active ingredients | |
| JP2008517977A5 (en) | ||
| JP2011503142A5 (en) | ||
| WO2004058303A3 (en) | Compositions of benzoquinolizine carboxylic acid antibiotic drugs | |
| JP4829322B2 (en) | Agents for foods that raise body temperature | |
| RU2009127858A (en) | PHARMACEUTICAL COMPOSITION, INCLUDING ALISKIREN AND AVOSENTAN |